Navigation Links
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Date:11/6/2008

a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200, 300 or 400 mg). Four weeks later, they were crossed over to a second single picoplatin dose administered via the alternative route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 and 100 mg).

Results showed that oral picoplatin can achieve oral bioavailability of up to 44 percent in the doses tested in the first arm. Results also showed that picoplatin oral bioavailability is linear, and maximum exposure to orally administered picoplatin was achieved at doses of 200 mg or greater. Additionally, following four weeks of dosing with either oral or intravenous picoplatin, only background levels of circulating platinum could be detected, suggesting no drug accumulation between dosing cycles.

There were no differences in pharmacokinetics observed, and all doses were well tolerated with no serious adverse events related to treatment noted following the oral dose. No myelosuppression occurred after oral dosing.

Poniard expects to present additional data from the trial at scientific meetings during 2009.

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum- based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Cynosure, Inc. (Nasdaq: CYNO ... treatment systems for high-volume applications, today reported financial results ... 2014 financial results incorporate the acquisition of Palomar Medical ... Second-Quarter 2014 Financial Highlights ... , Non-GAAP net income of $7.1 million, or ...
(Date:7/29/2014)... 2014   What:   ... present data from a Phase I clinical trial of ... stop Parkinson,s disease progression. The Michael J. Fox Foundation ... will discuss the impact of the results for patients ... July 31, 2014         ...
(Date:7/29/2014)... , July 29, 2014  Drug development for ... rising incidence rates and the intense need for ... vaccine. Change is underway as the market moves ... highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive bodybuilding guide for men who ... by up to 50 pounds in within a few ... that will help keep their shoulders healthy and avoid the ... the Critical Bench Program 2.0 uncovers to learners the reason ...
(Date:7/30/2014)... July 30, 2014 pMD, the ... communication, launched an Observation Result (ORU) interface to ... pMD’s cardiology customers are using the ORU interface ... their test interpretations for electrocardiograms, echocardiograms, and stress ... the hospital, the cardiology system produces electronic data ...
(Date:7/29/2014)... 2014 VisitandCare.com today announced ... added to the company’s exclusive network to help couples ... joint efforts — as top fertility clinics in Spain, ... affordable, state-of-the-art, and successful IVF treatments. , The exclusive ... comprehensive study by professionals at VisitandCare.com. The goal is ...
(Date:7/29/2014)... Phytceramides are a natural anti-aging tool for improving skin, and ... Today is the last day to nab a free download copy ... book is also sold in hard copy. , "I am working ... were so new and very unknown in the U.S. that ... Kathy Heshelow, founder of Sublime Beauty®. "It is an easy yet ...
(Date:7/29/2014)... 2014 The Mesothelioma Applied Research ... Cancer Coalition, led advocacy efforts among its members ... established Congressional Caucus on the Deadliest Cancers. , ... features the following 20 members: , Rep. Matt Salmon (AZ-5) ... 2, 2014, Rep. Zoe Lofgren (CA-19) – June 19, 2014, ...
Breaking Medicine News(10 mins):Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3
... Clinicians to Overcome the Limitations of Conventional Pulse Oximetry, ... Calif., June 3 Masimo, the inventor of Pulse ... announced it has completed the conversion of Duke ... , , "Ultimately, the decision to convert ...
... ... for Christian Community. Christian Care Ministry, Inc. is a not-for-profit religious organization that facilitates ... ... 2009 -- Medi-Share is a member-based program where members share in each ...
... Genetics is pleased to announce the launch of whole-genome ... Oligo Array, which is designed to identify chromosomal abnormalities ... partnership with Baylor College of Medicine , Ambry ... comprehensive, clinically-validated genetic tests available using array comparative genomic ...
... Lauded in Healthcare Category for ,Visionary Application of Information ... , , MADISON, N.J., June 3 ... world,s leading provider of diagnostic testing, information and services, ... Ltd. has been recognized as a Laureate by the ...
... , WASHINGTON, June 3 New questions and valuable answers ... at www.tenquestionstoanswer.org , the latest in the Heinz Family Philanthropies ... designed to help families make the best long-term care decisions. Available ... manage long-term care. , , "We want ...
... STAMFORD, Conn., June 3 FUJIFILM Medical Systems ... today that the company has taken several steps ... company is already an experienced virtualization provider with ... successfully implemented across the U.S. Now, to ...
Cached Medicine News:Health News:Leading University Hospital Completes System-Wide Conversion to Masimo SET(R) Pulse Oximetry 2Health News:Leading University Hospital Completes System-Wide Conversion to Masimo SET(R) Pulse Oximetry 3Health News:Leading University Hospital Completes System-Wide Conversion to Masimo SET(R) Pulse Oximetry 4Health News:Medi-Share Program Announces New Healthcare Program Offerings for Christian Community 2Health News:'Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis' 2Health News:'Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis' 3Health News:Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program 2Health News:Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program 3Health News:Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program 4Health News:New From the Heinz Family Philanthropies: 10 Questions and Valuable Answers to Help Families Manage Long-Term Care 2Health News:New From the Heinz Family Philanthropies: 10 Questions and Valuable Answers to Help Families Manage Long-Term Care 3Health News:New From the Heinz Family Philanthropies: 10 Questions and Valuable Answers to Help Families Manage Long-Term Care 4Health News:New From the Heinz Family Philanthropies: 10 Questions and Valuable Answers to Help Families Manage Long-Term Care 5Health News:Fujifilm Takes Virtualization Technology to Next Level 2Health News:Fujifilm Takes Virtualization Technology to Next Level 3
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
... or antepartum GBS results can be available in ... revolutionary in vitro diagnostic test is the first ... in the clinical lab and near-patient by non-laboratory ... 24 hours a day, 365 days a year. ...
Medicine Products: